Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage ...

An update from TScan Therapeutics ( (TCRX) ) is now available.

TScan Therapeutics (TCRX) has entered into a term loan facility with Silicon Valley Bank, a division of First Citizens Bank, for up to $52.5 ...

TScan Therapeutics secures a $52.5 million term loan from Silicon Valley Bank to enhance financial flexibility and support cancer therapies. TScan Therapeutics, Inc. has announced a term loan ...

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...